Ocugen Inc

OCGN
1,5399
0,2099 (15,78%)
Ultimo aggiornamento: 19:17:43
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/5/202413:30GLOBEOcugen to Host Conference Call on Tuesday, May 14 at 8:30..
02/5/202413:15GLOBEOcugen Announces CSO to Present on Modifier Gene Therapy at..
29/4/202412:45GLOBEOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data..
26/4/202415:05GLOBEUPDATE -- Ocugen to Present on Modifier Gene Therapy..
26/4/202412:30GLOBEOcugen to Present on Modifier Gene Therapy Platform at..
19/4/202413:13GLOBEOcugen Announces Dosing Completion of Subjects with..
12/4/202413:30GLOBEOcugen to Participate in Fireside Chat at the Emerging..
10/4/202413:02GLOBEOcugen, Inc. Announces Positive Scientific Advice from the..
08/4/202412:30GLOBEOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment..
05/4/202413:02GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
02/4/202414:00GLOBEOcugen Provides Business Update with Certain Financials for..
02/4/202400:08GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
01/4/202423:43GLOBEOcugen to Host Conference Call on Tuesday, April 2 at 8:30..
18/3/202411:30GLOBEOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical..
13/3/202413:00GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
06/3/202413:30GLOBEOcugen to Present at Investing in Cures Summit
28/2/202414:00GLOBEOcugen Clinical Showcase Webcast Now Available
26/2/202414:30GLOBEOcugen Chairman and CEO to present at Abu Dhabi Family..
22/2/202422:05GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
21/2/202422:05GLOBEOcugen to Present at 2024 BIO CEO & Investor Conference
21/2/202417:22EDGAR2Form 8-K - Current report
14/2/202413:30GLOBEOcugen to Host Clinical Showcase in New York City..
31/1/202414:00GLOBEOcugen to Present at Pharma Market Research Conference
16/1/202413:30GLOBEOcugen, Inc. Announces Bob Smith Joins Business Advisory..
08/1/202412:05EDGAR2Form 8-K - Current report
05/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202321:09EDGAR2Form 8-K - Current report
21/12/202312:30GLOBEOcugen Gains FDA Alignment on Key Aspects of OCU400—Modifier..
19/12/202313:30GLOBEOcugen Announces OCU400 Receives Regenerative Medicine..
13/12/202313:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
29/11/202313:30GLOBEOcugen CEO to Present at NobleCon19 – Noble Capital Markets’..
10/11/202313:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
09/11/202314:02EDGAR2Form 8-K - Current report
09/11/202313:02EDGAR2Form 8-K - Current report
09/11/202312:30GLOBEOcugen Provides Business Update with Third Quarter 2023..
09/11/202312:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:45GLOBEOcugen CSO to Participate in 4th Annual Dry AMD Therapeutic..
02/11/202312:30GLOBEOcugen to Host Conference Call on Thursday, November 9 at..
10/10/202315:05EDGAR2Form 8-K - Current report
10/10/202312:30GLOBEOcugen Mucosal Vaccine Candidate OCU500 Selected by..
04/10/202313:00GLOBEOcugen to Present at the 2023 Cell & Gene Meeting on the..
29/9/202313:30GLOBEOcugen CSO to Participate in 4th Annual Gene Therapy for..
28/9/202301:30GLOBEOcugen to Participate in Fireside Chat at Chardan’s 7th..
21/9/202313:30GLOBEOcugen, Inc. Announces Connie Collingsworth Joins Business..
20/9/202314:00GLOBEOcugen to Participate in Panel at Cantor Fitzgerald Global..
19/9/202322:54EDGAR2Form 8-K - Current report
19/9/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 1,34 Min: 1,33 Max: 1,56
Chiusura: 1,33

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network